Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer (Q40853983)

24 September 2017

1 reference

title

Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer (English)

1 reference

24 September 2017

1 reference

1 reference

1 reference

van Laar JA

1

1 reference

24 September 2017

Rustum YM

2

1 reference

24 September 2017

Ackland SP

3

1 reference

24 September 2017

van Groeningen CJ

4

1 reference

24 September 2017

Peters GJ

5

1 reference

24 September 2017

publication date

1 February 1998

1 reference

European Journal of Cancer

24 September 2017

published in

1 reference

24 September 2017

volume

34

1 reference

24 September 2017

issue

3

1 reference

24 September 2017

page(s)

296-306

1 reference

Cancer in the European community and its member states

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Fluorouracil: biochemistry and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Clinical relevance of biochemical modulation of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Hepatic arterial chemotherapy for metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Circadian patterning of continuous floxuridine infusion reduces toxicity and allows higher dose intensity in patients with widespread cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Do antimetabolites interfere with the glycosylation of cellular glycoconjugates?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Loss of murine tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: Enzyme activity and inhibition by 5-fluoro-2′-deoxyuridine-5′-monophosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Phase I and pharmacokinetic evaluation of floxuridine/leucovorin given on the Roswell Park weekly regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Effect of Uridine on the Metabolism of 5-Fluorouracil in the CD8F 1 Murine Mammary Carcinoma System

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Transport and intracellular metabolism of fluorinated pyrimidines in cultured cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Clinical pharmacology of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Modulation of fluoropyrimidines by leucovorin: Rational and status

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Quantification of 5-fluorouracil incorporation into RNA of human and murine tumors as measured with a sensitive gas chromatography-mass spectrometry assay

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Cytotoxic mechanisms of 5-fluoropyrimidines. Relationships with poly(ADP-ribose) polymerase activity, DNA strand breakage and incorporation into nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Increased formation of nucleotide derivatives of 5-fluorouridine in hepatoma cells treated with inhibitors of pyrimidine synthesis and D-galactosamine

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonacetyl)-L-aspartate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Separation of several 5-fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-fluorouracil-nucleotide sugars

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Changes in glycosylation of L1210 cells after exposure to various antimetabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Experiments on the efficacy and toxicity of locoregional chemotherapy of liver tumors with 5-fluoro-2'-deoxyuridine (FUDR) and 5-fluorouracil (5-FU) in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Locoregional administration of 5-fluoro-2'-deoxyuridine (FdUrd) in Novikoff hepatoma in the rat: effects of dose and infusion time on tumor growth and on FdUrd metabolite levels in tumor tissue as determined by 19F-NMR spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Effects of antitumor agents on subcutaneous implants and hepatic metastases of colon carcinoma 26 in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Modulation of the antitumour activity of cisplatin alone and in combination with 5-fluoro-2'-deoxyuridine by N-phosphonacetyl-l-aspartate in murine colon carcinoma no. 26

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Continuous or bolus chemotherapy with 5-fluoro-2'-deoxyuridine in transplanted experimental liver tumors?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Short-term intrahepatic FUdR infusion combined with bolus mitomycin C: reduced risk for developing drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

The effects on liver metastases of circadian patterned continuous hepatic artery infusion of FUDR

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Regional chemotherapy for colorectal liver metastases: thirty years without patient benefit

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Alternating Hepatic Intra-Arterial Floxuridine and Fluorouracil: A Less Toxic Regimen for Treatment of Liver Metastases From Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

CPT-11 (Irinotecan) in the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

‘Tomudex’ (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900366-3

7 January 2021

10.1016/S0959-8049(97)00366-3

Identifiers

DOI

1 reference

24 September 2017

1 reference